Last reviewed · How we verify
BPaL(M) regimen
BPaL(M) regimen is a Anti-tuberculosis combination regimen Small molecule drug developed by Asan Medical Center. It is currently FDA-approved for Extensively drug-resistant tuberculosis (XDR-TB), Multidrug-resistant tuberculosis (MDR-TB). Also known as: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin.
BPaL(M) is a combination regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin that targets multiple pathways in Mycobacterium tuberculosis to overcome drug resistance.
BPaL(M) is a combination regimen of bedaquiline, pretomanid, linezolid, and moxifloxacin that targets multiple pathways in Mycobacterium tuberculosis to overcome drug resistance. Used for Extensively drug-resistant tuberculosis (XDR-TB), Multidrug-resistant tuberculosis (MDR-TB).
At a glance
| Generic name | BPaL(M) regimen |
|---|---|
| Also known as | Bedaquiline, Pretomanid, Linezolid, Moxifloxacin |
| Sponsor | Asan Medical Center |
| Drug class | Anti-tuberculosis combination regimen |
| Target | Multiple: ATP synthase (bedaquiline), cell wall synthesis (pretomanid), ribosomal protein synthesis (linezolid), DNA gyrase (moxifloxacin) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The regimen combines four anti-tuberculosis agents with complementary mechanisms: bedaquiline inhibits ATP synthase, pretomanid is a prodrug activated by mycobacterial enzymes to disrupt cell wall synthesis, linezolid inhibits protein synthesis, and moxifloxacin inhibits DNA gyrase. This multi-target approach is designed to treat drug-resistant tuberculosis, particularly extensively drug-resistant (XDR-TB) and multidrug-resistant (MDR-TB) strains.
Approved indications
- Extensively drug-resistant tuberculosis (XDR-TB)
- Multidrug-resistant tuberculosis (MDR-TB)
Common side effects
- Peripheral neuropathy
- QT prolongation
- Hepatotoxicity
- Gastrointestinal disturbances
- Anemia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BPaL(M) regimen CI brief — competitive landscape report
- BPaL(M) regimen updates RSS · CI watch RSS
- Asan Medical Center portfolio CI
Frequently asked questions about BPaL(M) regimen
What is BPaL(M) regimen?
How does BPaL(M) regimen work?
What is BPaL(M) regimen used for?
Who makes BPaL(M) regimen?
Is BPaL(M) regimen also known as anything else?
What drug class is BPaL(M) regimen in?
What development phase is BPaL(M) regimen in?
What are the side effects of BPaL(M) regimen?
What does BPaL(M) regimen target?
Related
- Drug class: All Anti-tuberculosis combination regimen drugs
- Target: All drugs targeting Multiple: ATP synthase (bedaquiline), cell wall synthesis (pretomanid), ribosomal protein synthesis (linezolid), DNA gyrase (moxifloxacin)
- Manufacturer: Asan Medical Center — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Extensively drug-resistant tuberculosis (XDR-TB)
- Indication: Drugs for Multidrug-resistant tuberculosis (MDR-TB)
- Also known as: Bedaquiline, Pretomanid, Linezolid, Moxifloxacin
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing